A RANDOMIZED TRIAL OF SWITCHING TREATMENT-EXPERIENCED ADULTS FROM PI/r TO DTG
Dolutegravir (DTG) has shown good efficacy and tolerability among treatment-experienced adults with HIV. Most HIV-infected adults in Kenya with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) failure are on ritonavir-boosted protease inhibitor (PI/r)-based second line regimens. We evaluated the efficacy and safety of switching virally suppressed adults from a second-line PI/r-containing regimen to a DTG-containing regimen,…